# US 6,730,659 B2 · Antimicrobial peptides and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,659 B2
- Document ID: US6730659B2
- Status: Granted
- Kind: B2
- Application number: 10/328,125
- Filed: 2002-12-20
- Published: 2004-03-11
- Granted: 2004-05-04
- Earliest claimed: 1999-03-01
- Assignees: The Board of Regents of the University of Oklahoma
- Inventors: H. Anne Pereira
- Web page: https://patentgrep.com/patent/US6730659B2

## CPC

- C07K 14/4723: {Cationic antimicrobial peptides, e.g. defensins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y10S 530/827: Proteins from mammals or birds
- Y10S 530/829: Blood
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.

## Claims

### Claim 1

A method of treating a bacterial infection in a subject, comprising:
administering a therapeutically effective amount of a peptide comprising a derivative of CAP37 peptide 23-42 (cationic antimicrobial protein of molecular weight 37 kDa) (SEQ ID NO:2) wherein one of the cysteine residues at positions 26 and 42 is substituted with a serine or threonine residue and one of the cysteine residues at positions 26 and 42 is left unsubstituted.

### Claim 2 (depends on 1)

The method of claim 1, the peptide derivative further comprising at least one of the substitutions comprising:
phenylalanine replaced by tyrosine;
glycine replaced by alanine;
valine replaced by alanine, leucine, or isoleucine;
alanine replaced by leucine, isoleucine or valine;
leucine replaced by alanine, isoleucine or valine;
isoleucine replaced by valine, leucine or alanine;
serine replaced by histidine, arginine, or lysine; and threonine replaced by serine.

### Claim 3

A method of treating septic shock in a subject or prophylactically preventing septic shock in a subject, comprising:
administering a therapeutically effective amount of a peptide comprising a derivative of CAP37 peptide 23-42 (cationic antimicrobial protein of molecular weight 37 kDa) (SEQ ID NO:2) wherein one of the cysteine residues at positions 26 and 42 is substituted with a serine or threonine residue and one of the cysteine residues at positions 26 and 42 is left unsubstituted.

### Claim 4 (depends on 3)

The method of claim 3, the peptide derivative further comprising at least one of the substitutions comprising:
phenylalanine replaced by tyrosine;
glycine replaced by alanine;
valine replaced by alanine, leucine, or isoleucine;
alanine replaced by leucine, isoleucine or valine;
leucine replaced by alanine, isoleucine or valine;
isoleucine replaced by valine, leucine or alanine;
serine replaced by histidine, arginine, or lysine; and
threonine replaced by serine.

### Claim 5

A method of treating a bacterial infection in a subject, comprising:
administering a therapeutically effective amount of a peptide having the sequence:
R-H-X1-X2-X3-X4-X5-X6-X7-H-X8-R-X9-X10-M-X11-X12-X13-X14-X15
wherein:
X1 is phe or tyr;
X2 is cys, ser, or thr;
X3 is gly or ala;
X4 is gly or ala;
X5-X8, X10, X12 and X13 are ala, leu, ile or val;
X9 is phe or tyr;
X11 is ser or thr;
X14 is ser, thr, his, arg or lys;
X15 is ser, cys or thr;
R is arg;
H is his; and
M is met; and with the proviso that when X2 is cys, X15 is ser or thr and when X15 is cys, X2 is ser or thr.

### Claim 6

A therapeutic composition, comprising:
a pharmaceutically acceptable carrier; and
a peptide comprising the amino acid sequence:
R-H-X1-X2-X3-X4-X5-X6-X7-H-X8-R-X9-X10-M-X11-X12-X13-X14-X15
wherein:
X1 is phe or tyr;
X2 is cys, ser, or thr;
X3 is gly or ala;
X4 is gly or ala;
X5-X8, X10, X12 and X13 are ala, leu, ile or val;
X9 is phe or tyr;
X11 is ser or thr;
X14 is ser, thr, his, arg or lys;
X15 is ser, cys or thr;
R is arg;
H is his; and
M is met; and with the proviso that when X2 is cys, X15 is ser or thr and when X15 is cys, X2 is ser or thr.
